I don't think Boston Scientific could have gotten its offer to $80 a share without Abbott. I don't think they could be there at all without what has in effect become, 'The Bank of Abbott.

We are following in the grand tradition of Berkeley engineering, as with Berkeley 's BSD UNIX operating system, in making our innovations freely available and unencumbered for research and possible commercialization in source code form.

I wouldn't expect these documents to affect this exuberant bidding.

Another reason companies are supporting the RAD Lab is to help UC Berkeley continue to produce new generations of young leaders in information technology.

Intellectual property issues rarely derail a merger. If there was an issue, there would probably be an economic adjustment between Abbott and Boston Scientific.

It's possible that Johnson & Johnson and Guidant have buried themselves in a room. The fact that nobody has spilled the beans yet doesn't mean that there aren't any beans to spill.

It's chest thumping. It's a lot of emotions. Most folks in this game have never met a deal they didn't like.